William Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
William Lee has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Dennis L. Kuchar
St Vincent's Hospital, Suite 802, 438 Victoria St., Darlinghurst, NSW 2010, Australia
3 shared publicationsErkan Ilhan
Department of Cardiac Sciences, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada
2 shared publicationsRajesh N. Subbiah
St Vincent's Hospital, Suite 802, 438 Victoria St., Darlinghurst, NSW 2010, Australia
2 shared publications- Satish R. Raj
Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
2 shared publications - Adam P. Hill
Victor Chang Cardiac Research Institute, Sydney, Australia
1 shared publication Andre Tay
St Vincent's Hospital, Suite 802, 438 Victoria St., Darlinghurst, NSW 2010, Australia
1 shared publication
Latest Publications
- 1 July 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (7) , 399-410
Action Potential Morphology Accurately Predicts Proarrhythmic Risk for Drugs With Potential to Prolong Cardiac Repolarization
BACKGROUND:Drug-induced or acquired long QT syndrome occurs as a result of the unintended disruption of cardiac repolarization due to drugs that block cardiac ion channels. These side effects have been responsible for the withdrawal of a range of drugs from market and are a common reason for termination of the development of new drugs in the preclinical stage. Existing approaches to risk prediction are expensive and overly sensitive meaning that recently there have been renewed efforts, largely driven by the comprehensive proarrhythmic assay initiative, to develop more accurate methods for allocation of proarrhythmic risk. METHODS:In this study, we aimed to quantify changes in the morphology of the repolarization phase of the cardiac action potential as an indicator of proarrhythmia, supposing that these shape changes might precede the emergence of ectopic depolarizations that trigger arrhythmia. To do this, we describe a new method of quantifying action potential morphology by measuring the radius of curvature of the repolarization phase both in simulated action potentials, as well as in action potentials measured from induced pluripotent stem cell-derived cardiomyocytes. Features derived from the curvature signal were used as inputs for logistic regressions to predict proarrhythmic risk. RESULTS:Optimal risk classifiers based on morphology were able to correctly classify risk to drugs in the comprehensive proarrhythmic assay initiative panels with very high accuracy (0.9375) and outperformed conventional metrics based on action potential duration at 90% repolarization, triangulation, and charge movement (qNet). CONCLUSIONS:Analysis of action potential morphology in response to proarrhythmic drugs improves prediction of torsadogenic risk. Furthermore, morphology metrics can be measured directly from the action potential, potentially eliminating the burden of undertaking complex screens of potency and drug-binding kinetics against multiple cardiac ion channels. As such, this method has the potential to improve and streamline regulatory assessment of proarrhythmia in preclinical drug development.
- 1 July 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (7) , 399-410
Action Potential Morphology Accurately Predicts Proarrhythmic Risk for Drugs With Potential to Prolong Cardiac Repolarization
BACKGROUND:Drug-induced or acquired long QT syndrome occurs as a result of the unintended disruption of cardiac repolarization due to drugs that block cardiac ion channels. These side effects have been responsible for the withdrawal of a range of drugs from market and are a common reason for termination of the development of new drugs in the preclinical stage. Existing approaches to risk prediction are expensive and overly sensitive meaning that recently there have been renewed efforts, largely driven by the comprehensive proarrhythmic assay initiative, to develop more accurate methods for allocation of proarrhythmic risk. METHODS:In this study, we aimed to quantify changes in the morphology of the repolarization phase of the cardiac action potential as an indicator of proarrhythmia, supposing that these shape changes might precede the emergence of ectopic depolarizations that trigger arrhythmia. To do this, we describe a new method of quantifying action potential morphology by measuring the radius of curvature of the repolarization phase both in simulated action potentials, as well as in action potentials measured from induced pluripotent stem cell-derived cardiomyocytes. Features derived from the curvature signal were used as inputs for logistic regressions to predict proarrhythmic risk. RESULTS:Optimal risk classifiers based on morphology were able to correctly classify risk to drugs in the comprehensive proarrhythmic assay initiative panels with very high accuracy (0.9375) and outperformed conventional metrics based on action potential duration at 90% repolarization, triangulation, and charge movement (qNet). CONCLUSIONS:Analysis of action potential morphology in response to proarrhythmic drugs improves prediction of torsadogenic risk. Furthermore, morphology metrics can be measured directly from the action potential, potentially eliminating the burden of undertaking complex screens of potency and drug-binding kinetics against multiple cardiac ion channels. As such, this method has the potential to improve and streamline regulatory assessment of proarrhythmia in preclinical drug development.
- Open Access
- 31 July 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 16 (6) , 849-860
Prolonged QT Interval in Cirrhosis: Twisting Time?
William Lee, Bert Vandenberk, Satish R. Raj, and Samuel S. Lee. Gut and Liver 2022;16:849-60. https://doi.org/10.5009/gnl210537
- 31 July 2022
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 16 (6) , 849-860
Open AccessProlonged QT Interval in Cirrhosis: Twisting Time?
William Lee, Bert Vandenberk, Satish R. Raj, and Samuel S. Lee. Gut and Liver 2022;16:849-60. https://doi.org/10.5009/gnl210537
- Open Access
- 6 April 2022
- Published by Elsevier in JACC: Case Reports
- Vol. 4 (7) , 402-405
Iatrogenic Arteriovenous Fistula
- 6 April 2022
- Published by Elsevier in JACC: Case Reports
- Vol. 4 (7) , 402-405
Open AccessIatrogenic Arteriovenous Fistula
- 22 November 2021
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 14 (12) , 1099-1101
Pharmacological Cardioversion of Atrial Tachyarrhythmias Using Single High-Dose Oral Amiodarone: A Systematic Review and Meta-Analysis
- 22 November 2021
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 14 (12) , 1099-1101
Pharmacological Cardioversion of Atrial Tachyarrhythmias Using Single High-Dose Oral Amiodarone: A Systematic Review and Meta-Analysis
- 3 February 2016
- Published by Oxford University Press (OUP) in EP Europace
Accelerated graft dysfunction in heart transplant patients with persistent atrioventricular conduction block
Aims Bradyarrhythmia following heart transplantation is common—∼7.5–24% of patients require permanent pacemaker (PPM) implantation. While overall mortality is similar to their non-paced counterparts, the effects of chronic right ventricular pacing (CRVP) in heart transplant patients have not been studied. We aim to examine the effects of CRVP on heart failure and mortality in heart transplant patients. Methods and results Records of heart transplant recipients requiring PPM at St Vincent's Hospital, Sydney, Australia between January 1990 and January 2015 were examined. Patient's without a right ventricular (RV) pacing lead or a follow-up time of P < 0.0001 by log-rank analysis, HR = 24.58). Non-pacing-dependent patients had reversible causes for heart failure, unrelated to pacing. In comparison, there was no other cause of heart failure in the pacing-dependent group. Conclusions Permanent atrioventricular block is rare in the heart transplant population. We have demonstrated CRVP as a potential cause of accelerated graft failure in pacing-dependent heart transplant patients.
- 3 February 2016
- Published by Oxford University Press (OUP) in EP Europace
Accelerated graft dysfunction in heart transplant patients with persistent atrioventricular conduction block
Aims Bradyarrhythmia following heart transplantation is common—∼7.5–24% of patients require permanent pacemaker (PPM) implantation. While overall mortality is similar to their non-paced counterparts, the effects of chronic right ventricular pacing (CRVP) in heart transplant patients have not been studied. We aim to examine the effects of CRVP on heart failure and mortality in heart transplant patients. Methods and results Records of heart transplant recipients requiring PPM at St Vincent's Hospital, Sydney, Australia between January 1990 and January 2015 were examined. Patient's without a right ventricular (RV) pacing lead or a follow-up time of P < 0.0001 by log-rank analysis, HR = 24.58). Non-pacing-dependent patients had reversible causes for heart failure, unrelated to pacing. In comparison, there was no other cause of heart failure in the pacing-dependent group. Conclusions Permanent atrioventricular block is rare in the heart transplant population. We have demonstrated CRVP as a potential cause of accelerated graft failure in pacing-dependent heart transplant patients.
- 8 March 2012
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 36 (5) , e153-e155
Isolated Ventricular Noncompaction: Implications for Mechanisms of Sudden Cardiac Death
We present a case of a young patient, whose first manifestation of isolated ventricular noncompaction (IVNC) was sudden cardiac arrest precipitated by ventricular fibrillation. Furthermore we had the rare opportunity to record the onset of subsequent episodes of ventricular fibrillation—with discussion on the mechanisms of ventricular arrhythmias in IVNC. (PACE 2013; 36:e153–e155)
- 8 March 2012
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 36 (5) , e153-e155
Isolated Ventricular Noncompaction: Implications for Mechanisms of Sudden Cardiac Death
We present a case of a young patient, whose first manifestation of isolated ventricular noncompaction (IVNC) was sudden cardiac arrest precipitated by ventricular fibrillation. Furthermore we had the rare opportunity to record the onset of subsequent episodes of ventricular fibrillation—with discussion on the mechanisms of ventricular arrhythmias in IVNC. (PACE 2013; 36:e153–e155)
- 1 October 2010
- Published by Elsevier in Heart Rhythm
- Vol. 7 (10) , 1509-1511
Profound bradycardia and hypotension in a normal heart
- 1 October 2010
- Published by Elsevier in Heart Rhythm
- Vol. 7 (10) , 1509-1511
Profound bradycardia and hypotension in a normal heart